Combining Antiangiogenic Therapy With Neoadjuvant Chemotherapy Increases Treatment Efficacy in Stage IIIA (N2) Non-Small Cell Lung Cancer Without Increasing Adverse Effects
Oncotarget - United States
doi 10.18632/oncotarget.11547
Full Text
Open PDFAbstract
Available in full text
Categories
Date
August 23, 2016
Authors
Publisher
Impact Journals, LLC